How mrd powering next wave precision oncology

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 02 Nov, 13:23 UTC

The Oncodetect® molecular residual disease test is giving clinicians insights that can reshape cancer treatment and monitoring.